Skip to main content

Luminol As In Situ Light Source in Meso-Tetraphenylporphyrin-Mediated Photodynamic Therapy

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

The light sources used in current photodynamic therapy are mainly lasers or light emitting diodes, which are not suitable to treat large-volume tumors and those located in the inner body. To overcome the limitation, we propose an in situ light source to activate the photosensitizer and kill the cancer cells directly. In the present work, we use luminol as light source and meso-tetraphenylporphyrin as the photosensitizer. According to the results, cells incubated with meso-tetraphenylporphyrin, subsequently triggered by luminol, decreased significantly in assays including cell viability and cytotoxicity, while the other groups showed only minor differences. The flow cytometric and fluorescent microscopy analysis showed similar results as well. In the analysis of cell death pathway, cell shrinkage was noticed after photodynamic therapy treatment, which might refer to apoptosis. Briefly, we suggest that luminol is a promising light source in meso-tetraphenylporphyrin-mediated photodynamic therapy for its greater penetration depth and well matched emission wavelength.

Keywords: In situ; apoptosis; current photodynamic; large-volume tumors; light source; light sources; luminal; meso-tetraphenylporphyrin; photodynamic therapy; photosensitizer

Document Type: Research Article

Publication date: 2013-03-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more